Position in EXEL
as of Jun 30, 2026
· filed Jul 6, 2026
Position Value
$367,539
+$235,224 QoQ
Shares Held
6,755
+119.0% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#57
of 112 holders
Holding Since
Dec 2021
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CoreCap Advisors, LLC holds $2,312,000 across 78 Biotechnology names. EXEL ranks #1 (15.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
6,755 | $367,539 | |
| 2 | MRNA |
Moderna, Inc.
|
4,595 | $321,787 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
3,000 | $244,530 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
442 | $219,554 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
315 | $196,415 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
280 | $150,346 | |
| 7 | ANIX |
Anixa Biosciences Inc
|
52,020 | $145,656 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
428 | $135,286 |
All Filings in EXEL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $367,539 | 6,755 | Shares | Sole | 2026-07-06 | |
| 2026-03-31 | $132,315 | 3,085 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $131 | 3 | Shares | Sole | 2026-01-13 | |
| 2025-09-30 | $137,157 | 3,321 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $663,139 | 15,044 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $704,027 | 19,069 | Shares | Sole | 2025-05-09 | |
| 2022-12-31 | $8,020 | 500 | Shares | Sole | 2023-02-10 | |
| 2022-06-30 | $10,410 | 500 | Shares | Sole | 2022-08-11 | |
| 2021-12-31 | $9,140 | 500 | Shares | Sole | 2022-02-10 | |
| No filing history on record for this holder in this stock. | ||||||